Dobutamine
Brand names: Dobutamine Injection
Dobutamine is an intravenous inotropic sympathomimetic used for short-term cardiac support in acute heart failure and low cardiac output states.
Adult dose
Paediatric dose
Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.
SPC §4.2: for all paediatric age groups (neonates to 18 years) an INITIAL dose of 5 micrograms/kg/minute, adjusted according to clinical response to 2-20 micrograms/kg/minute, is recommended (unit is micrograms/kg/MINUTE - not mg/kg). Occasionally a dose as low as 0.5-1.0 micrograms/kg/minute will produce a response. The minimum effective dose in children is believed to be higher than in adults, while the maximum tolerated dose is believed to be lower - use caution with high doses. Response varies greatly between paediatric patients, so the dose cannot be determined a priori and must be titrated. Reducing or stopping the infusion is usually all that is required for rapid reversal of undesirable effects. NEONATAL INTENSIVE CARE (SPC method of administration): dilute 30 mg/kg body weight to a final volume of 50 ml of infusion fluid - an infusion rate of 0.5 ml/hour then provides a dose of 5 micrograms/kg/minute. Increments in heart rate and blood pressure appear more frequent and intense in children; pulmonary wedge pressure may not fall as it does in adults and may rise, especially in infants under one year. Dobutamine stress echocardiography is for the adult population only. Verify against a children's formulary.
Contraindications
- Hypersensitivity to dobutamine or to any of the excipients, including patients with bronchial asthma who are hypersensitive to sulfites (sodium metabisulfite)
- Mechanical obstruction of ventricular filling and/or outflow - e.g. pericardial tamponade, constrictive pericarditis, hypertrophic obstructive cardiomyopathy, severe aortic stenosis
- Hypovolaemic conditions
- Phaeochromocytoma
- Additionally for stress echocardiography: recent myocardial infarction (within the last 30 days), unstable angina, left main stem stenosis, haemodynamically significant LV outflow obstruction or valvular defect, severe heart failure (NYHA III-IV), predisposition to or history of clinically significant/chronic arrhythmia (particularly recurrent persistent VT), significant conduction disturbance, acute pericarditis/myocarditis/endocarditis, aortic dissection or aneurysm, poor sonographic imaging conditions, inadequately controlled arterial hypertension
Side effects
- Very common: increase in heart rate of 30 beats/min or more, and blood pressure increase of 50 mmHg or more (greater rises in patients with arterial hypertension)
- Common: blood pressure decrease, ventricular dysrhythmia and dose-dependent ventricular extrasystoles; increased ventricular rate in atrial fibrillation (digitalise before infusion)
- Common: anginal pain and palpitations; vasoconstriction, particularly in patients previously treated with beta blockers
- Common: headache, nausea, bronchospasm, shortness of breath, exanthema, eosinophilia and inhibition of thrombocyte aggregation (with infusion over several days)
- Uncommon/rare: hypersensitivity reactions including rash and eosinophilic myocarditis; sulfite-related allergic reactions including anaphylaxis; ventricular tachycardia, ventricular fibrillation, atrial fibrillation; very rarely bradycardia, myocardial ischaemia, myocardial infarction, cardiac arrest and hypokalaemia
Clinical monograph
How it works
It acts predominantly on beta-1 adrenergic receptors to increase myocardial contractility and cardiac output, with relatively modest effects on heart rate at usual infusion rates.
Prescribing in practice
- Correct hypovolaemia before starting, and give by controlled infusion with continuous cardiac and blood-pressure monitoring as it can provoke tachyarrhythmias and ischaemia.
- Use with caution in significant outflow obstruction and in atrial fibrillation, where it may increase ventricular rate.
- Titrate to clinical and haemodynamic response and avoid abrupt large changes in infusion rate.
Monitoring
Monitor continuous ECG, blood pressure, heart rate and, where available, cardiac output and urine output throughout the infusion.
Counselling the patient
- Explain to the patient that this medicine supports the heart's pumping and is given as a closely monitored drip.
- Advise reporting palpitations or chest discomfort to staff immediately.
- Reassure that the dose is adjusted to their response and stopped gradually.
Evidence & guidelines
Dobutamine is a standard agent for short-term inotropic support in low cardiac output states and is widely used in critical care.
Reference: ESC Cardiogenic Shock Guidelines; NICE NG106; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- MAGGIC Heart Failure Risk Score · Heart Failure
- Long QT Syndrome (Schwartz Score) · Channelopathy / Sudden Cardiac Death
- C-Peptide to Glucose Ratio · Diabetes Classification
- International Staging System (ISS) for Multiple Myeloma · Multiple Myeloma
- Revised ISS (R-ISS) for Multiple Myeloma · Haematological Malignancy
- International Staging System for Multiple Myeloma (ISS) · Oncology
- Difficult Airway Algorithm (DAS) · DAS 2015; Royal College of Anaesthetists
- Major Haemorrhage Protocol · NICE NG24; UK MHP guidelines
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Featured in these MRCEM clinical pathways
Dobutamine is a core drug in the following exam-focused workups on our sister siteReviseMRCEM.
MRCEM Primary / Intermediate / OSCE candidates: each pathway includes exam-style questions, RCEM/NICE citations, and FAQ summaries.